Nov 1, 2007
By:
Joanna Breitstein
|
Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.
From his new post, former FDA commissioner Mark McClellan talks about the current safety equation
Oct 1, 2007
By:
Joanna Breitstein
|
You have to admit: Mark McClellan, MD, has quite a resumé. But after you've been the commissioner of FDA and the administrator of the Centers for Medicare and Medicaid Services (CMS), what comes next?
Oct 1, 2007
By:
Joanna Breitstein
|
The Schering-Plough story offers a fascinating tale of a turnaround. But it's also a story of how a leader can right the ship of the beleaguered modern-day pharma company. Given the challenges the industry faces, models of effective leadership are precious. Who can today's execs learn from? To some extent or other, many leaders need to set themselves to the task of studying, emulating, and being a leader like Fred Hassan.
David Barlow is the closest thing you can find to a pharma-industry ecologist. He takes companies that deal with technology that Big Pharma won't touch and turns them into drug powerhouses.
Gary Herman, head of the new experimental-medicine division, is teaching Merck's storied scientists to fail...faster
Sep 1, 2007
By:
Walter Armstrong, Marylyn Donahue, Special Projects Editor
|
That was the collective vow sworn by Big Pharma last December following Pfizer's $1 billion–down–the–tubes withdrawal of the cholesterol compound they had touted as the most important drug of the decade. The question is, What's the right organizational construct to support innovation—or at least to stop Phase III failures?
When Merck KGaA and Serono merged last September, some said it was a shotgun wedding, while others called it a good fit. Now that the honeymoon is over, Pharm Exec takes the measure of the match.
Sep 1, 2007
By:
Walter Armstrong
|
It's testimony to the high anxiety—and hectic activity—in the industry that the merger of German chemicals-to-pharmaceuticals firm Merck KGaA and Swiss biotech Serono elicited only faint fanfare. Both family-owned drugmakers boast an illustrious heritage, but their union garnered none of the pomp and circumstance befitting a marriage of European royalty.
With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, J&J's little company is in it to win it. And end it.
Jul 30, 2007
By:
Walter Armstrong
|
Tibotec is set to launch a second revolution in HIV treatment—Âand make a run at Glaxo, BMS, and Abbott, the longtime market kingpins
Jul 25, 2007
By:
Carolynne Van Houten
|
Severin Schwan takes over at Roche
Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine
Jun 1, 2007
By:
Patrick Clinton, Jill Wechsler
|
There's tremendous opportunity for us to understand how drugs can be used even better to get the right outcome, not only how to contain them in order to avoid complications or adverse events
